E Fund Management Co. Ltd. bought a new position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 189,432 shares of the company’s stock, valued at approximately $1,421,000.
Other institutional investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD acquired a new position in Kyverna Therapeutics during the first quarter worth $23,093,000. Jennison Associates LLC acquired a new position in Kyverna Therapeutics during the first quarter worth $34,743,000. Janus Henderson Group PLC acquired a new position in Kyverna Therapeutics during the first quarter worth $15,041,000. TD Asset Management Inc acquired a new position in Kyverna Therapeutics during the second quarter worth $677,000. Finally, Vanguard Group Inc. acquired a new position in Kyverna Therapeutics during the first quarter worth $6,563,000. 18.08% of the stock is currently owned by institutional investors and hedge funds.
Kyverna Therapeutics Stock Performance
KYTX stock opened at $6.66 on Wednesday. The company’s 50-day simple moving average is $8.06 and its 200 day simple moving average is $13.97. Kyverna Therapeutics, Inc. has a 52 week low of $6.30 and a 52 week high of $35.06.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on KYTX. JPMorgan Chase & Co. lowered their target price on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. HC Wainwright decreased their price objective on shares of Kyverna Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Thursday, August 15th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.40.
Check Out Our Latest Report on KYTX
Kyverna Therapeutics Company Profile
Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
Featured Articles
- Five stocks we like better than Kyverna Therapeutics
- How Investors Can Find the Best Cheap Dividend Stocks
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Investing In Preferred Stock vs. Common Stock
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- How to Effectively Use the MarketBeat Ratings Screener
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Want to see what other hedge funds are holding KYTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report).
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.